← All trials
NCT05033444
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 17, 2021
- Primary completion
- Nov 30, 2021
- Completion date
- Nov 30, 2021
- First posted
- Sep 2, 2021
- Last posted
- Sep 24, 2021
- Enrollment
- 24
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Odyssey PharmaceuticalsLead sponsor
- Nucleus Network LtdOverall official - principal investigator
- Avance Clinical Pty Ltd.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.